ChenGuang Biotech Group Co., Ltd.

SZSE:300138 Stock Report

Market Cap: CN¥4.3b

ChenGuang Biotech Group Past Earnings Performance

Past criteria checks 1/6

ChenGuang Biotech Group has been growing earnings at an average annual rate of 12.3%, while the Food industry saw earnings growing at 2.5% annually. Revenues have been growing at an average rate of 17.1% per year. ChenGuang Biotech Group's return on equity is 3.7%, and it has net margins of 2.2%.

Key information

12.3%

Earnings growth rate

10.9%

EPS growth rate

Food Industry Growth7.2%
Revenue growth rate17.1%
Return on equity3.7%
Net Margin2.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Apr 25
Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Recent updates

A Piece Of The Puzzle Missing From ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) 43% Share Price Climb

Oct 08
A Piece Of The Puzzle Missing From ChenGuang Biotech Group Co., Ltd.'s (SZSE:300138) 43% Share Price Climb

ChenGuang Biotech Group (SZSE:300138) Might Be Having Difficulty Using Its Capital Effectively

Sep 30
ChenGuang Biotech Group (SZSE:300138) Might Be Having Difficulty Using Its Capital Effectively

Return Trends At ChenGuang Biotech Group (SZSE:300138) Aren't Appealing

May 13
Return Trends At ChenGuang Biotech Group (SZSE:300138) Aren't Appealing

Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

Apr 25
Impressive Earnings May Not Tell The Whole Story For ChenGuang Biotech Group (SZSE:300138)

ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Apr 21
ChenGuang Biotech Group Co., Ltd. (SZSE:300138) Just Reported, And Analysts Assigned A CN¥17.66 Price Target

Revenue & Expenses Breakdown

How ChenGuang Biotech Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SZSE:300138 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 246,927150-1411
30 Jun 246,694287-110
31 Mar 246,786389-45
31 Dec 236,87248600
30 Sep 236,66949622692
30 Jun 236,737492237113
31 Mar 236,529462243129
31 Dec 226,296434249129
30 Sep 226,465429255135
30 Jun 226,002403244116
31 Mar 225,44638022899
31 Dec 214,87435221195
30 Sep 214,41032219088
30 Jun 214,18630418991
31 Mar 214,18828516583
01 Jan 213,91326819283
30 Sep 203,66725221168
30 Jun 203,48123523148
31 Mar 203,28820628152
31 Dec 193,26519426949
30 Sep 193,22616527245
30 Jun 193,37816225443
31 Mar 193,13914623234
01 Jan 193,06314521829
30 Sep 182,79915518726
30 Jun 182,77915915342
31 Mar 182,80715514035
31 Dec 172,77214315229
30 Sep 172,78012918921
30 Jun 172,3841202090
31 Mar 172,2591112110
31 Dec 162,141921910
30 Sep 161,824991410
30 Jun 161,636791220
31 Mar 161,474801090
31 Dec 151,268691000
30 Sep 151,24659970
30 Jun 151,28757960
31 Mar 151,20524950
31 Dec 141,20722920
30 Sep 141,23821880
30 Jun 141,1744900
31 Mar 141,1313990
31 Dec 131,186101030

Quality Earnings: 300138 has a large one-off loss of CN¥91.3M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: 300138's current net profit margins (2.2%) are lower than last year (7.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 300138's earnings have grown by 12.3% per year over the past 5 years.

Accelerating Growth: 300138's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 300138 had negative earnings growth (-69.8%) over the past year, making it difficult to compare to the Food industry average (-5.8%).


Return on Equity

High ROE: 300138's Return on Equity (3.7%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 15:31
End of Day Share Price 2024/12/25 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ChenGuang Biotech Group Co., Ltd. is covered by 7 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Siyuan DongChangjiang Securities Co. LTD.
Wendan WangChina International Capital Corporation Limited
Guang Yao ChenFounder Securities Co., Ltd.